Recent News

VGXI, Inc. today announced the execution of a Master Product Sale Agreement to supply plasmid between its parent company, VGX International, and BioCancell Therapeutics.  BioCancell is a biopharmaceuticals corporation specializing in the development of Patient-Oriented, Targeted Therapy for the treatment of numerous types of cancer.  Products under the Agreement will be manufactured… Read More »

Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) announced today that it has contracted with VGXI, Inc. (The Woodlands, TX) (“VGXI”) to supply the plasmid portion of the Company’s combination therapy consisting of the Factor 5A gene and siRNA against Factor 5A. Senesco has previously reported positive preclinical in vivo results using… Read More »

VGX Pharmaceuticals announced today that it has submitted two separate investigational new drug (IND) applications to the U.S. Food and Drug Administration (FDA) for Phase I clinical studies of VGX-3100 and VGX-3400. Both candidate vaccines are based on VGX’s SynCon™ vaccine technology, and they have been developed using VGX’s integrated DNA Vaccines… Read More »

VGX Pharmaceuticals (VGX) today announced that the Company has signed a multi-year supply agreement to provide plasmid DNA to support the ongoing toxicology and clinical trials of the United Kingdom Cystic Fibrosis Gene Therapy Consortium comprising over 80 scientists and clinicians in Edinburgh, London and Oxford dedicated to the search for effective… Read More »

VGX Pharmaceuticals today announced it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for Phase I clinical studies of VGX-3200 in late stage cancer patients. VGX-3200 is an injectable DNA plasmid-based therapeutic that expresses human Growth Hormone Releasing Hormone (GHRH) protein. VGX’s innovative DNA… Read More »

VGX Pharmaceuticals today announced that the DNA plasmid-based product manufactured by VGX on behalf of Nucleonics,Inc. has entered Phase I human clinical trials in the United States and Europe for the treatment of chronic Hepatitis B virus (HBV) infection. The Nucleonics’ HBV clinical candidate (NUC B1000) is an expressed interfering RNA (eiRNA)… Read More »

VGX Animal Health, Inc. (VGXAH), a developer of cutting edge technologies for animal health applications, announced today the approval by the Australian Pesticides and Veterinary Medicines Authority (APVMA) of LifeTide™ SW 5, the Company’s leading Growth Hormone Releasing Hormone (GHRH) product for swine therapy. LifeTide™ SW 5 is an injectable DNA plasmid… Read More »

VGX Pharmaceuticals, Inc., a leading developer of novel drugs and vaccines, announced today that it has signed a collaboration and license agreement with VGX International, Inc. The Agreement provides the technical support and manufacturing process technology necessary for VGX International to construct and operate a large-scale cGMP, DNA plasmid manufacturing facility in… Read More »

VGX Pharmaceuticals, Inc., a leading manufacturer of cGMP-grade DNA plasmids, announced today that it has expanded its manufacturing capacity with the installation and testing of a new 500-liter scale fermentor in its cGMP manufacturing facility in The Woodlands, Texas. The new fermentor gives VGX significantly more flexibility than its current 100-liter production… Read More »

VGX Pharmaceuticals today announced that it has been granted U.S. Patent number 7,238,522 covering its DNA plasmid manufacturing technology. The patent entitled, “Device and Methods for Biomaterial Production” represents the first to issue of a series of applications related to VGX’s novel approach to DNA plasmid manufacturing. “We are very pleased to… Read More »